DelMar Pharmaceuticals to Present Promising New Data on their Anti-Cancer Drug

Spotlight Companies  |

DelMar Pharmaceuticals Inc. ($DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, continues to make significant progress with their innovative anti-cancer drug, VAL-083. The company announced that Jeffrey Bacha, CEO of DelMar Pharmaceuticals, will present an update on the company's ongoing clinical trial of VAL-083 at the 8th Annual LD Micro Main Event. The presentation will take place on Wednesday, December 2, 2015, at 3:30 p.m. at the Luxe Sunset Hotel in Los Angeles.

This new data will also be presented at DelMar will be presented at the Society for Neuro-Oncology Annual Meeting on November 19-22, 2015. 

LD Micro’s annual Main Event micro-cap conference is designed to highlight and showcase the next generation of great companies to private and institutional investors, as well as to analysts, bloggers, and the media. LD Micro also publishes reports on select companies throughout the year.

VAL-083, a first-in-class, small-molecule chemotherapeutic, has demonstrated positive outcomes in the treatment of various cancers, including small cell lung cancer, brain, cervical, ovarian tumors. While VAL-083 is approved to treat chronic myelogenous leukemia lung cancer in China, The US National Cancer Institute has sponsored more than 40 Phase I and II clinical studies, and the anti-cancer drug is currently undergoing clinical trials in the US.

This year has been filled with milestones for DelMar. The company recently presented data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on the potential of VAL-083 in the treatment of non-small cell lung cancer. Furthermore,DelMar completed enrollment of a Phase II clinical trial of VAL-083 in refractory GBM.

DelMar’s frequent presentations on VAL-083’s promising treatment potential continues to shine a light on up and coming alternatives to traditional chemotherapy options. With an upcoming Phase II clinical trial, DelMar Pharmaceuticals aims to usher in the modern age of effective cancer treatment. had the opportunity to interview Jeffrey Bacha, President and CEO of DelMar Pharmaceuticals. The interview can be watched here. For more information about DelMar Pharmaceuticals, visit

Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.